Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High – Still a Buy?

Posted by Geri Gentry on Jul 2nd, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $125.39 and last traded at $123.00, with a volume of 964233 shares traded. The stock had previously closed at $123.77.

Analyst Upgrades and Downgrades

MIRM has been the subject of several analyst reports. Morgan Stanley increased their price objective on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Thursday, June 11th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. TD Cowen lifted their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, Weiss Ratings downgraded Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $139.80.

Check Out Our Latest Report on Mirum Pharmaceuticals

Mirum Pharmaceuticals Trading Up 2.9%

The firm has a fifty day simple moving average of $101.93 and a two-hundred day simple moving average of $95.13. The firm has a market capitalization of $7.35 billion, a P/E ratio of -8.85 and a beta of 0.48. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. On average, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,594 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30. Following the sale, the senior vice president directly owned 5,835 shares of the company’s stock, valued at $594,878.25. This represents a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 37,594 shares of company stock worth $3,608,758. Company insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth $1,478,000. TD Asset Management Inc bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $1,129,000. Tudor Investment Corp ET AL bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $2,027,000. Nan Fung Trinity HK Ltd. lifted its holdings in Mirum Pharmaceuticals by 45.6% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after purchasing an additional 71,214 shares in the last quarter. Finally, SBI Okasan Asset Management Co.Ltd. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $1,283,000.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.